Targeting trpv1: Challenges and issues in pain management

Open Drug Discovery Journal

Volumn 2, Issue SPEC. ISS.2, 2010, Pages 37-49

  Trevisani, Marcello ^a   Szallasi, Arpad ^b,c  

^a PharmEste srl   (Italy)

^b Medical Center   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Capsaicin; Heat; Hyperthermia; Neuropathic pain; Pain; Resiniferatoxin; TRP channel; TRPV1 antagonists

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; 1 (5 ISOQUINOLINYL) 3 [4 (TRIFLUOROMETHYL)BENZYL]UREA; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ALDEA; AMG 0610; AMG 6880; AMG 7472; ANALGESIC AGENT; ANALGESIC, ANTIINFLAMMATORY, ANTIRHEUMATIC AND ANTIGOUT AGENTS; ANANDAMIDE; AZD 1386; CAPSAICIN; CAPSAZEPINE; CIS CAPSAICIN; DWP 05195; GRC 6211; JTS 653; JYL 1421; MK 2295; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; N (4 TERTIARYBUTYLPHENYL) 4 (3 CHLOROPHYRIDIN 2 YL)TETRAHYDROPYRAZINE 1 (2H)CARBOXAMIDE; N [2,3 (4 DIHYDROXYPHENYL)ETHYL]EICOSATETRAENAMIDE; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; N [4 [[[[(4 TERTBUTYLBENZYL)AMINO]CARBONOTHIOYL]AMINO]METHYL] 2 FLUOROPHENYL]METHANESULFONAMIDE; NE 19950; OLVANIL; PHE 377; PLACEBO; PROTEIN INHIBITOR; QUETENZA; RESINIFERATOXIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL VANILLOID 1 ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; WN 1001;

ANALGESIA; APPLICATION SITE BURNING; BONE CANCER; CANCER PAIN; CHRONIC INFLAMMATION; CHRONIC PAIN; DIABETIC NEUROPATHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ERYTHEMA; GASTROESOPHAGEAL REFLUX; HEADACHE; HEAT SENSATION; HIV ASSOCIATED NEPHROPATHY; HUMAN; HYPERTHERMIA; INFLAMMATORY PAIN; ISCHEMIA; KNEE OSTEOARTHRITIS; MIGRAINE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; OVERACTIVE BLADDER; PAIN ASSESSMENT; PAIN THRESHOLD; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECTUM DISEASE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TASTE; TISSUE INJURY; TOOTH PAIN; URINE INCONTINENCE;

EID: 83255182363     PISSN: None     EISSN: 18773818     Source Type: Journal    
DOI: 10.2174/1877381801002030037     Document Type: Review

References (147)

1. Dhalla, I.A.; Mamdani, M.M.; Sivilotti, M.L.; Kopp, A.; Qureshi, O.; Juurlink, D.N. Prescribing of opioid analgesics and related mortality before and after the introduction of long-actingoxycodone. Canadian Med. Assoc. J. 2009, 181, 891-896.
2. Campbell, J.; Basbaum, A.; Dray, A.; Dubner, R.; Dworkin, R.; Sang, C. Emerging strategies for the treatment of neuropathic pain. IASP Press, Seattle, WA, 2006.
3. Gidal, B.E. New and emerging treatment options for neuropathic pain. Am. J. Manag. Care., 2006, 12, S269-S278.
4. Katz, W.A.; Barkin, R.L. Dilemmas in chronic/persistent pain management. Am. J. Ther., 2008, 15, 256-264.
5. Caterina, M.J. Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292, R64-R76.
6. Ferrer-Montiel, A.; Garcia-Martinez, C.; Morenilla-Palao, C.; Garcia-Sanz, N.; Fernandez-Carvajal, A.; Fernandez-Ballester, G.; Planells-Cases, R. Molecular architecture of the vanilloid receptor. Insights for drug design. Eur. J. Biochem., 2004, 271, 1820-1826.
7. Caterina, M.J.; Julius, D. The vanilloid receptor: a molecular gateway to the pain pathway. Ann. Rev. Neurosci., 2001, 24, 487-517.
8. Immke, D.C.; Gavva, N.R. The TRPV1 receptor and nociception. Semin. Cell Dev. Biol., 2006, 17, 582-591.
9. Di Marzo, V.; Blumberg, P.M.; Szallasi, A. Endovanilloid signaling in pain. Curr. Opin. Neurobiol., 2002, 12, 372-379.
10. Suh, Y.G.; Oh, U. Activation and activators of TRPV1 and their pharmaceutical implication. Curr. Pharm. Des., 2005, 11, 2687-2698.
11. Bolcskei, K.; Helyes, Z.; Szabo, A.; Sandor, K.; Elekes, K.; Nemeth, J.; Almasi, R.; Pinter, E.; Petho, G.; Szolcsanyi, J. Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice. Pain, 2005, 117, 368-376.
12. Cui, M.; Honore, P.; Zhong, C.; Gauvin, D.; Mikusa, J.; Hernandez, G.; Chandran, P.; Gomtsyan, A.; Brown, B.; Bayburt, E.K.; Marsh, K.; Bianchi, B.; McDonald, H.; Niforatos, W.; Neelands, T.R.; Moreland, R.B.; Decker, M.W.; Lee, C.H.; Sullivan, J.P.; Faltynek, C.R. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J. Neurosci., 2006, 26, 9385-9393.
13. Szolcsanyi, J.; Bartho, L. Capsaicin-sensitive non-cholinergic excitatory innervation of the guinea-pig tracheobronchial smooth muscle. Neurosci. Lett., 1982, 34, 247-251.
14. Maggi, C.A.; Meli, A. The sensory-efferent function of capsaicinsensitive sensory neurons. Gen. Pharmacol., 1988, 19, 1-43.
15. Holzer, P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol. Rev., 1991, 43, 143-201.
16. Szallasi, A.; Blumberg, P.M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol. Rev., 1999, 51, 159-212.
17. Geppetti, P.; Holzer, P. Neurogenic inflammation. CRC Press: Boca Raton, 1996.
18. Butler, C.A.; Heaney, L.G. Neurogenic inflammation and asthma. Inflamm. Allergy Drug Targets, 2007, 6, 127-132.
19. Trevisani, M.; Smart, D.; Gunthorpe, M.J.; Tognetto, M.; Barbieri, M.; Campi, B.; Amadesi, S.; Gray, J.; Jerman, J.C.; Brough, S.J.; Owen, D.; Smith, G. D.; Randall, A.D.; Harrison, S.; Bianchi, A.; Davis, J.B.; Geppetti, P. Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat. Neurosci., 2002, 5, 546-551.
20. Patapoutian, A.; Peier, A.M.; Story, G.M.; Viswanath, V. ThermoTRP channels and beyond: mechanisms of temperature sensation. Nat. Rev. Neurosci., 2003, 4, 529-539.
21. Siemens, J.; Zhou, S.; Piskorowski, R.; Nikai, T.; Lumpkin, E.A.; Basbaum, A.I.; King, D.; Julius, D. Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature, 2006, 444, 208-212.
22. Szallasi, A.; Cortright, D.N.; Blum, C.A.; Eid, S.R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov., 2007, 6, 357-372.
23. Cromer, B.A.; McIntyre, P. Painful toxins acting at TRPV1. Toxicon., 2008, 51, 163-173.
24. Pingle, S.C.; Matta, J.A.; Ahern, G.P. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb. Exp. Pharmacol., 2007, (179), pp. 155-171.
25. Vellani, V.; Mapplebeck, S.; Moriondo, A.; Davis, J.B.; McNaughton, P.A. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J. Physiol., 2001, 534, 813-825.
26. Gunthorpe, M.J.; Benham, C.D.; Randall, A.; Davis, J.B. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol. Sci., 2002, 23, 183-191.
27. Crandall, M.; Kwash, J.; Yu, W.; White, G. Activation of protein kinase C sensitizes human VR1 to capsaicin and to moderate decreases in pH at physiological temperatures in Xenopus oocytes. Pain, 2002, 98, 109-117.
28. Caterina, M.J.; Leffler, A.; Malmberg, A.B.; Martin, W.J.; Trafton, J.; Petersen-Zeitz, K.R.; Koltzenburg, M.; Basbaum, A. I.; Julius, D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science, 2000, 288, 306-313.
29. Davis, J. B.; Gray, J.; Gunthorpe, M. J.; Hatcher, J.P.; Davey, P.T.; Overend, P.; Harries, M.H.; Latcham, J.; Clapham, C.; Atkinson, K.; Hughes, S.A.; Rance, K.; Grau, E.; Harper, A.J.; Pugh, P. L.; Rogers, D.C.; Bingham, S.; Randall, A.; Sheardown, S.A. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature, 2000, 405, 183-187.
30. Malmberg, A.; Bley, K. Turning up the heat on pain: TRPV1 receptors in pain and inflammation. Birkhäuser, Basel, Switzerland 2005.
31. Gunthorpe, M.J.; Szallasi, A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr. Pharm. Des., 2008, 14, 32-41.
32. Reeh, P.W.; Petho, G. Nociceptor excitation by thermal sensitization-a hypothesis. Prog. Brain Res., 2000, 129, 39-50.
33. Premkumar, L.S.; Ahern, G.P. Induction of vanilloid receptor channel activity by protein kinase C. Nature, 2000, 408, 985-990.
34. Tominaga, M.; Wada, M.; Masu, M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc. Natl. Acad. Sci. USA, 2001, 98, 6951-6956.
35. Kagaya, M.; Lamb, J.; Robbins, J.; Page, C. P.; Spina, D. Characterization of the anandamide induced depolarization of guinea-pig isolated vagus nerve. Br. J. Pharmacol., 2002, 137, 39-48.
36. Olah, Z.; Karai, L.; Iadarola, M.J. Protein kinase C(alpha) is required for vanilloid receptor 1 activation. Evidence for multiple signaling pathways. J. Biol. Chem., 2002, 277, 35752-35759.
37. Bhave, G.; Hu, H.J.; Glauner, K.S.; Zhu, W.; Wang, H.; Brasier, D.J.; Oxford, G.S.; Gereau, R.W. t. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc. Natl. Acad. Sci. USA, 2003, 100, 12480-12485.
38. Varga, A.; Bolcskei, K.; Szoke, E.; Almasi, R.; Czeh, G.; Szolcsanyi, J.; Petho, G. Relative roles of protein kinase A and protein kinase C in modulation of transient receptor potential vanilloid type 1 receptor responsiveness in rat sensory neurons in vitro and peripheral nociceptors in vivo. Neuroscience, 2006, 140, 645-657.
39. Vetter, I.; Wyse, B.D.; Monteith, G.R.; Roberts-Thomson, S.J.; Cabot, P.J. The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMPdependent protein kinase A pathway. Mol. Pain 2006, 2, 22.
40. Zhang, X.; McNaughton, P.A. Why pain gets worse: the mechanism of heat hyperalgesia. J. Gen. Physiol., 2006, 128, 491-493.
41. Prescott, E.D.; Julius, D. A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science, 2003, 300, 1284-1288.
42. Brauchi, S.; Orta, G.; Mascayano, C.; Salazar, M.; Raddatz, N.; Urbina, H.; Rosenmann, E.; Gonzalez-Nilo, F.; Latorre, R. Dissection of the components for PIP2 activation and thermosensation in TRP channels. Proc. Natl. Acad. Sci. USA, 2007, 104, 10246-10251.
43. Lishko, P.V.; Procko, E.; Jin, X.; Phelps, C.B.; Gaudet, R. The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel sensitivity. Neuron., 2007, 54, 905-918.
44. Stein, A.T.; Ufret-Vincenty, C.A.; Hua, L.; Santana, L.F.; Gordon, S.E. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J. Gen. Physiol., 2006, 128, 509-522.
45. Lukacs, V.; Thyagarajan, B.; Varnai, P.; Balla, A.; Balla, T.; Rohacs, T. Dual regulation of TRPV1 by phosphoinositides. J. Neurosci., 2007, 27, 7070-7080.
46. 2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMP-dependent protein kinase. J. Biol. Chem., 2005, 280, 13424-3432.
47. Bhave, G.; Zhu, W.; Wang, H.; Brasier, D.J.; Oxford, G.S.; Gereau, R.W. t. cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron., 2002, 35, 721-731.
48. Mohapatra, D.P.; Nau, C. Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J. Biol. Chem., 2003, 278, 50080-50090.
49. Numazaki, M.; Tominaga, T.; Takeuchi, K.; Murayama, N.; Toyooka, H.; Tominaga, M. Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc. Natl. Acad. Sci. USA, 2003, 100, 8002-8006.
50. Rosenbaum, T.; Gordon-Shaag, A.; Munari, M.; Gordon, S.E. Ca2+/calmodulin modulates TRPV1 activation by capsaicin. J. Gen. Physiol., 2004, 123, 53-62.
51. Jung, J.; Shin, J.S.; Lee, S.Y.; Hwang, S. W.; Koo, J.; Cho, H.; Oh, U. Phosphorylation of vanilloid receptor 1 by Ca2+/calmodulindependent kinase II regulates its vanilloid binding. J. Biol. Chem., 2004, 279, 7048-7054.
52. Wood, J. Capsaicin in the study of pain. Academic Press, New York, NY 1993.
53. Szallasi, A.; Cruz, F.; Geppetti, P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol. Med., 2006, 12, 545-554.
54. Knotkova, H.; Pappagallo, M. and Szallasi, A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin. J. Pain, 2008, 24, 142-154.
55. Remadevi, R.; Szallasi, A. Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. IDrugs, 2008, 11, 120-132.
56. Avelino, A.; Cruz, F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch. Pharmacol., 2006, 373, 287-299.
57. Roberts, L.A.; Connor, M. TRPV1 antagonists as a potential treatment for hyperalgesia. Recent Patents CNS Drug Discov., 2006, 1, 65-76.
58. Gharat, L.; Szallasi, A. Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists. Expert Opin. on Therap. Patents, 2008, 18, 159-209.
59. Chizh, B.A.; O'Donnell, M.B.; Napolitano, A.; Wang, J.; Brooke, A.C.; Aylott, M.C.; Bullman, J.N.; Gray, E.J.; Lai, R.Y.; Williams, P.M.; Appleby, J.M. The effects of the TRPV1 antagonist SB- 705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain, 2007, 132, 132-141.
60. Faltynek, C.; Gomtsyan, A. Vanilloid receptor TRPV1 in drug discovery: targeting pain and other pathological disorders. John Wiley&Sons, 2009.
61. http://clinicaltrials.gov/ct2/results?term=ABT-102.
62. http://clinicaltrials.gov/ct2/results?term=AZD-1386.
63. http://clinicaltrials.gov/ct2/show/NCT00281684?cond.
64. http://clinicaltrials.gov/ct2/show/NCT00969787?term=05195&rank=1.
65. http://www.clinicaltrials.gov/ct2/show/NCT00387140?
66. http://www.daewoong.co.kr/www_pharm/english_new/aboutus/whatsnews_view.asp?idx=60652.
67. http://www.glenmarkpharma.com/media/pdf/releases/GRC_6211.pdf
68. http://www.glenmarkpharma.com/research/clinical.html.
69. http://www.jt.com/investors/results/pharmaceuticals/pdf/P.L.20080207_E.pdf.
70. http://www.neurogen.com/index.php?option=com_content&view=article&id=47&Itemid=2&phpMyAdmin=34a2390c0eecf801a871d79668695b95.
71. http://www.pharmeste.com/include/PHE377.pdf.
72. http://clinicaltrials.gov/ct2/results?term=ALGRX-4975.
73. http://clinicaltrials.gov/ct2/results?term=civamide.
74. http://clinicaltrials.gov/ct2/results?term=NGX-4010.
75. Wang, X.; Miyares, R.L.; Ahern, G.P. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces shortterm food intake in mice via capsaicin receptor TRPV1. J. Physiol., 2005, 564, 541-547.
76. Christoph, T.; Bahrenberg, G.; De Vry, J.; Englberger, W.; Erdmann, V.A.; Frech, M.; Kogel, B.; Rohl, T.; Schiene, K.; Schroder, W.; Seibler, J.; Kurreck, J. Investigation of TRPV1 lossof- function phenotypes in transgenic shRNA expressing and knockout mice. Mol. Cell. Neurosci., 2008, 37, 579-589.
77. Christoph, T.; Gillen, C.; Mika, J.; Grunweller, A.; Schafer, M.K.; Schiene, K.; Frank, R.; Jostock, R.; Bahrenberg, G.; Weihe, E.; Erdmann, V.A.; Kurreck, J. Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1. Neurochem. Int., 2007, 50, 281-290.
78. Christoph, T.; Grunweller, A.; Mika, J.; Schafer, M.K.; Wade, E.J.; Weihe, E.; Erdmann, V.A.; Frank, R.; Gillen, C.; Kurreck, J. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem. Biophys. Res. Commun., 2006, 350, 238-243.
79. Kasama, S.; Kawakubo, M.; Suzuki, T.; Nishizawa, T.; Ishida, A.; Nakayama, J. RNA interference-mediated knock-down of transient receptor potential vanilloid 1 prevents forepaw inflammatory hyperalgesia in rat. Eur. J. Neurosci., 2007, 25, 2956-2963.
80. Klionsky, L.; Tamir, R.; Holzinger, B.; Bi, X.; Talvenheimo, J.; Kim, H.; Martin, F.; Louis, J.C.; Treanor, J.J.; Gavva, N.R. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation. J. Pharmacol. Exp. Ther., 2006, 319, 192-198.
81. Mezey, E.; Toth, Z.E.; Cortright, D.N.; Arzubi, M.K.; Krause, J.E.; Elde, R.; Guo, A.; Blumberg, P.M.; Szallasi, A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. USA, 2000, 97, 3655-3660.
82. Roberts, J.C.; Davis, J.B.; Benham, C.D. [3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res., 2004, 995, 176-183.
83. Szabo, T.; Biro, T.; Gonzalez, A.F.; Palkovits, M.; Blumberg, P.M. Pharmacological characterization of vanilloid receptor located in the brain. Brain Res. Mol. Brain Res., 2002, 98, 51-57.
84. Acs, G.; Palkovits, M.; Blumberg, P.M. Specific binding of [3H]resiniferatoxin by human and rat preoptic area, locus ceruleus, medial hypothalamus, reticular formation and ventral thalamus membrane preparations. Life Sci., 1996, 59, 1899-1908.
85. Millan, M.J. The induction of pain: an integrative review. Prog. Neurobiol., 1999, 57, 1-164.
86. Liapi, A.; Wood, J.N. Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur. J. Neurosci., 2005, 22, 825-834.
87. Sasamura, T.; Sasaki, M.; Tohda, C.; Kuraishi, Y. Existence of capsaicin-sensitive glutamatergic terminals in rat hypothalamus. Neuroreport, 1998, 9, 2045-2048.
88. Bodnar, R.J.; Kirchgessner, A.; Nilaver, G.; Mulhern, J.; Zimmerman, E.A. Intraventricular capsaicin: alterations in analgesic responsivity without depletion of substance P. Neuroscience, 1982, 7, 631-638.
89. Bodnar, R.J.; Simone, D.A.; Kordower, J. H.; Kirchgessner, A.L.; Nilaver, G. Capsaicin treatment and stress-induced analgesia. Pharmacol. Biochem. Behav., 1983, 18, 65-71.
90. Santos, A.R.; Calixto, J.B. Ruthenium red and capsazepine antinociceptive effect in formalin and capsaicin models of pain in mice. Neurosci. Lett., 1997, 235, 73-76.
91. Nolano, M.; Simone, D.A.; Wendelschafer-Crabb, G.; Johnson, T.; Hazen, E.; Kennedy, W.R. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain, 1999, 81, 135-145.
92. Reynolds, J.E.F. Martindale: the extra pharmacopoeia. Royal Pharmaceutical Society, 1999, 32nd edn.
93. Britain, B. M. A. R. P. S. o. G. British national formulary. BMA. 2003, (No 45).
94. Rains, C.; Bryson, H.M. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in postherpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging, 1995, 7, 317-328.
95. Karai, L.; Brown, D.C.; Mannes, A.J.; Connelly, S.T.; Brown, J.; Gandal, M.; Wellisch, O.M.; Neubert, J.K.; Olah, Z.; Iadarola, M.J. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J. Clin. Invest., 2004, 113, 1344-1352.
96. Menendez, L.; Juarez, L.; Garcia, E.; Garcia-Suarez, O.; Hidalgo, A.; Baamonde, A. Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci. Lett., 2006, 393, 70-73.
97. Dray, A.; Bettaney, J.; Rueff, A.; Walpole, C.; Wrigglesworth, R. NE-19550 and NE-21610, antinociceptive capsaicin analogues: studies on nociceptive fibres of the neonatal rat tail in vitro. Eur. J. Pharmacol., 1990, 181, 289-293.
98. Janusz, J.M.; Buckwalter, B.L.; Young, P.A.; LaHann, T.R.; Farmer, R.W.; Kasting, G.B.; Loomans, M.E.; Kerckaert, G.A.; Maddin, C.S.; Berman, E.F. Vanilloids. 1. Analogs of capsaicin with antinociceptive and antiinflammatory activity. J. Med Chem., 1993, 36, 2595-2604.
99. Walpole, C.S.; Wrigglesworth, R.; Bevan, S.; Campbell, E.A.; Dray, A.; James, I.F.; Masdin, K.J.; Perkins, M.N.; Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond B-region. J. Med. Chem., 1993, 36, 2373-2380.
100. Urban, L.; Campbell, E.A.; Panesar, M.; Patel, S.; Chaudhry, N.; Kane, S.; Buchheit, K.; Sandells, B. and James, I. F. In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue. Pain, 2000, 89, 65-74.
101. Walpole, C.S.; Wrigglesworth, R.; Bevan, S.; Campbell, E.A.; Dray, A.; James, I.F.; Perkins, M.N.; Reid, D.J.; Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic A-region. J. Med. Chem., 1993, 36, 2362-2372.
102. Walpole, C.S.; Wrigglesworth, R.; Bevan, S.; Campbell, E.A.; Dray, A.; James, I.F.; Masdin, K.J.; Perkins, M.N.; Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain C-region. J. Med. Chem., 1993, 36, 2381-2389.
103. Wrigglesworth, R.; Walpole, C.S.; Bevan, S.; Campbell, E.A.; Dray, A.; Hughes, G.A.; James, I.; Masdin, K.J.; Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics. J. Med. Chem., 1996, 39, 4942-4951.
104. Cantillon, M.; Hughes, S.; Moon, A.; Vause, E.; Sykes, D. Safety, tolerability and efficacy of ALGRX 4975 in osteoarthritis of the knee. J. Pain Off. J. Am. Pain Soc., 2005, 6.
105. Diamond, E.; Richards, P.; Miller, T. ALGRX 4975 reduces pain of intermetatarsal neuroma: preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial. J. Pain Off. J. Am. Pain Soc., 2006, 7.
106. Richards, P.; Vasko, G.; IStasko, I.; Lacko, M.; Hewson, G. (312/759): ALGRX 4975 reduces pain of acute lateral epicondylitis: preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial. J. Pain Off. J. Am. Pain Soc., 2006, 7.
107. Aasvang, E.K.; Hansen, J.B.; Malmstrom, J.; Asmussen, T.; Gennevois, D.; Struys, M.M.; Kehlet, H. The effect of wound instillation of a novel purified capsaicin formulation on postherniotomy pain: a double-blind, randomized, placebocontrolled study. Anesth. Analg., 2008, 107, 282-291.
108. Saper, J.R.; Klapper, J.; Mathew, N.T.; Rapoport, A.; Phillips, S.B.; Bernstein, J.E. Intranasal civamide for the treatment of episodic cluster headaches. Arch. Neurol., 2002, 59, 990-994.
109. Diamond, S.; Freitag, F.; Phillips, S.B.; Bernstein, J.E.; Saper, J.R. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia, 2000, 20, 597-602.
110. www.clinicaltrials.gov/ct2/show/NCT00845923
111. Simpson, D.M.; Brown, S., Tobias, J. Controlled trial of highconcentration capsaicin patch for treatment of painful HIV neuropathy. Neurology, 2008, 70, 2305-2313.
112. Simpson, D.M.; Estanislao, L.; Brown, S.J.; Sampson, J. An openlabel pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J. Pain Symptom Manage., 2008, 35, 299-306.
113. Bevan, S.; Hothi, S.; Hughes, G.; James, I.F.; Rang, H.P.; Shah, K.; Walpole, C.S.; Yeats, J.C. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br. J. Pharmacol., 1992, 107, 544-552.
114. Weil, A.; Moore, S.E.; Waite, N.J.; Randall, A.; Gunthorpe, M.J. Conservation of functional and pharmacological properties in the distantly related temperature sensors TRVP1 and TRPM8. Mol. Pharmacol., 2005, 68, 518-527.
115. Xing, H.; Chen, M.; Ling, J.; Tan, W.; Gu, J.G. TRPM8 mechanism of cold allodynia after chronic nerve injury. J. Neurosci., 2007, 27, 13680-13690.
116. Holzer, P. The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. Br. J. Pharmacol., 2008, 22, 22.
117. Gavva, N.R.; Tamir, R.; Klionsky, L.; Norman, M.H.; Louis, J.C.; Wild, K.D. and Treanor, J.J. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol. Pharmacol., 2005, 68, 1524-1533.
118. Lehto, S.G.; Tamir, R.; Deng, H.; Klionsky, L.; Kuang, R.; Le, A.; Lee, D.; Louis, J.C.; Magal, E.; Manning, B.H.; Rubino, J.; Surapaneni, S.; Tamayo, N.; Wang, T.; Wang, J.; Wang, W.; Youngblood, B.; Zhang, M.; Zhu, D.; Norman, M.H.; Gavva, N.R. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1Hinden- 4-yl)-3-(2-(piperidin-1-yl)-4-(trifluorom ethyl)phenyl)- acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J. Pharmacol. Exp. Ther., 2008, 326, 218-229.
119. Seabrook, G.R.; Sutton, K.G.; Jarolimek, W.; Hollingworth, G.J.; Teague, S.; Webb, J.; Clark, N.; Boyce, S.; Kerby, J.; Ali, Z.; Chou, M.; Middleton, R.; Kaczorowski, G.; Jones, A.B. Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodoresiniferatoxin. J. Pharmacol. Exp. Ther., 2002, 303, 1052-1060.
120. Gavva, N.R.; Klionsky, L.; Qu, Y.; Shi, L.; Tamir, R.; Edenson, S.; Zhang, T.J.; Viswanadhan, V.N.; Toth, A.; Pearce, L.V.; Vanderah, T.W.; Porreca, F.; Blumberg, P.M.; Lile, J.; Sun, Y.; Wild, K.; Louis, J.C.; Treanor, J.J. Molecular determinants of vanilloid sensitivity in TRPV1. J. Biol. Chem., 2004, 279, 20283-20295.
121. Neelands, T.R.; Jarvis, M.F.; Han, P.; Faltynek, C.R.; Surowy, C.S. Acidification of rat TRPV1 alters the kinetics of capsaicin responses. Mol. Pain, 2005, 1, 28.
122. Gunthorpe, M.J.; Rami, H.K.; Jerman, J.C.; Smart, D.; Gill, C.H.; Soffin, E.M.; Luis H.S.; Lappin, S.C.; Egerton, J.; Smith, G.D.; Worby, A.; Howett, L.; Owen, D.; Nasir, S.; Davies, C.H.; Thompson, M.; Wyman, P.A.; Randall, A.D.; Davis, J.B. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology, 2004, 46, 133-149.
123. Behrendt, H.J.; Germann, T.; Gillen, C.; Hatt, H.; Jostock, R. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br. J. Pharmacol., 2004, 141, 737-745.
124. Walker, K.M.; Urban, L.; Medhurst, S.J.; Patel, S.; Panesar, M.; Fox, A.J.; McIntyre, P. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther., 2003, 304, 56-62.
125. Pomonis, J.D.; Harrison, J.E.; Mark, L.; Bristol, D.R.; Valenzano, K.J.; Walker, K. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2- yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II in vivo characterization in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther., 2003, 306, 387-393.
126. Yamamoto, W.; Sugiura, A.; Nakazato-Imasato, E.; Kita, Y. Characterization of primary sensory neurons mediating static and dynamic allodynia in rat chronic constriction injury model. J. Pharm. Pharmacol., 2008, 60, 717-722.
127. Honore, P.; Wismer, C.T.; Mikusa, J.; Zhu, C.Z.; Zhong, C.; Gauvin, D.M.; Gomtsyan, A.; El Kouhen, R.; Lee, C.H.; Marsh, K.; Sullivan, J.P.; Faltynek, C.R.; Jarvis, M.F. A-425619[1- isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J. Pharmacol. Exp. Ther., 2005, 314, 410-421.
128. Swanson, D.M.; Dubin, A.E.; Shah, C.; Nasser, N.; Chang, L.; Dax, S.L.; Jetter, M.; Breitenbucher, J.G.; Liu, C.; Mazur, C.; Lord, B.; Gonzales, L.; Hoey, K.; Rizzolio, M.; Bogenstaetter, M.; Codd, E.E.; Lee, D.H.; Zhang, S.P.; Chaplan, S.R.; Carruthers, N.I. Identification and biological evaluation of 4-(3- trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5- trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem., 2005, 48, 1857-1872.
129. Zhong, C.; Gauvin, D.; Mikusa, J.; Chandran, P.; Hernandez, G.; Lee, L.; Brown, B.; McDonald, H.; Moreland, R.; Decker, M.W.; Honore, M.; Cui, M.; Faltynek, C.R. The novel and potent TRPV1 antagonist, A-784168, is a broad-spectrum analgesic in preclinical pain models. Washington, DC: Society for Neuroscience, 2005.
130. Trevisani, M.; Fruttarolo, F.; Pavani, M.; Campi, B.; Gatti, R.; De Siena, G.; Prosdocimi, M.; Napoletano, M.; Varani, K.; Borea, P.; Baraldi, P.G.; Semeraro, C.; Geppetti, P. V377, a potent TRPV1 antagonist for pain management. European Opioid Conference (EOC) - European Neuropeptide Club (ENC) joint meeting, 2008.
131. Surowy, C.S.; Neelands, T.R.; Bianchi, B. R.; McGaraughty, S.; El Kouhen, R.; Han, P.; Chu, K.L.; McDonald, H.A.; Vos, M.; Niforatos, W.; Bayburt, E.K.; Gomtsyan, A.; Lee, C.H.; Honore, P.; Sullivan, J.P.; Jarvis, M.F.; Faltynek, C.R. (R)-(5-tert-butyl-2,3- dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. J. Pharmacol. Exp. Ther., 2008, 326, 879-888.
132. Gomtsyan, A.; Bayburt, E.K.; Schmidt, R. G.; Surowy, C.S.; Honore, P.; Marsh, K. C.; Hannick, S.M.; McDonald, H.A.; Wetter, J.M.; Sullivan, J.P.; Jarvis, M.F.; Faltynek, C.R.; Lee, C.H. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3- (1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management. J. Med. Chem., 2008, 51, 392-395.
133. Wallace, M.S. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev. Neurother., 2006, 6, 1423-1428.
134. Brown, D.C.; Iadarola, M.J.; Perkowski, S.Z.; Erin, H.; Shofer, F.; Laszlo, K.J.; Olah, Z.; Mannes, A. J. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology, 2005, 103, 1052-1059.
135. Hori, T. Capsaicin and central control of thermoregulation. Pharmacol Ther., 1984, 26, 389-416.
136. Bannon, A.; Davis, J.; Zhu, D.; Norman, M.; Doherty, E.; Magal, E. and Treanor, J. Involvement of TRPV1 in the regulation of bodytemperature in rats and mice. Society for neuroscience annual meeting program, Vol. No. 890.24, San Diego, CA, 2004.
137. Gavva, N.R.; Bannon, A.W.; Surapaneni, S.; Hovland, Jr. D.N.; Lehto, S.G.; Gore, A.; Juan, T.; Deng, H.; Han, B.; Klionsky, L.; Kuang, R.; Le, A.; Tamir, R.; Wang, J.; Youngblood, B.; Zhu, D.; Norman, M.H.; Magal, E.; Treanor, J.J.; Louis, J.C. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J. Neurosci., 2007, 27, 3366-3374.
138. Romanovsky, A.A.; Almeida, M.C.; Garami, A.; Steiner, A.A.; Norman, M.H.; Morrison, S.F.; Nakamura, K.; Burmeister, J.J.; Nucci T.B. The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. Pharmacol. Rev. 2009, 61, 228-261.
139. Gavva, N.R. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol. Sci., 2008, 19, 19.
140. Gavva, N.R.; Treanor, J.J.; Garami, A.; Fang, L.; Surapaneni, S.; Akrami, A.; Alvarez, F.; Bak, A.; Darling, M.; Gore, A.; Jang, G.R.; Kesslak, J.P.; Ni, L.; Norman, M.H.; Palluconi, G.; Rose, M.J.; Salfi, M.; Tan, E.; Romanovsky, A.A.; Banfield, C.; Davar, G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain, 2008, 136, 202-210.
141. Steiner, A.A.; Turek, V.F.; Almeida, M.C.; Burmeister, J.J.; Oliveira, D.L.; Roberts, J.L.; Bannon, A.W.; Norman, M. H.; Louis, J.C.; Treanor, J.J.; Gavva, N.R.; Romanovsky, A.A. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic colddefense effectors. J. Neurosci., 2007, 27, 7459-7468.
142. Gavva, N.R.; Bannon, A.W.; Hovland, D. N. Jr.; Lehto, S.G.; Klionsky, L.; Surapaneni, S.; Immke, D.C.; Henley, C.; Arik, L.; Bak, A.; Davis, J.; Ernst, N.; Hever, G.; Kuang, R.; Shi, L.; Tamir, R.; Wang, J.; Wang, W.; Zajic, G.; Zhu, D.; Norman, M.H.; Louis, J.C.; Magal, E.; Treanor, J.J. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J. Pharmacol. Exp. Ther., 2007, 323, 128-137.
143. Garcia-Martinez, C.; Humet, M.; Planells-Cases, R.; Gomis, A.; Caprini, M.; Viana, F.; De La Pena, E.; Sanchez-Baeza, F.; Carbonell, T.; De Felipe, C.; Perez-Paya, E.; Belmonte, C.; Messeguer, A.; Ferrer-Montiel, A. Attenuation of thermal nociception and hyperalgesia by VR1 blockers. Proc. Natl. Acad. Sci. USA, 2002, 99, 2374-2379.
144. Tang, L.; Chen, Y.; Chen, Z.; Blumberg, P. M.; Kozikowski, A.P.; Wang, Z.J. Antinociceptive pharmacology of N-(4-chlorobenzyl)- N'-(4-hydroxy-3-iodo-5-methoxybenzyl) thiourea, a high-affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor. J. Pharmacol. Exp. Ther., 2007, 321, 791-798.
145. Eid, S.R. To feel or not to feel - targeting the heat sensor trpv1 for pain treatment. keystone meeting on neurobiology of pain and analgesia. http://www.keystonesymposia.org, Santa Fe, New Mexico, 2009.
146. Chizh, B.A.; Sang, C.N. Use of sensory methods for detecting target engagement in clinical trials of new analgesics. Neurotherapeutics, 2009, 6, 749-754.
147. http://www.qutenza.com/